JP2010512342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512342A5 JP2010512342A5 JP2009540497A JP2009540497A JP2010512342A5 JP 2010512342 A5 JP2010512342 A5 JP 2010512342A5 JP 2009540497 A JP2009540497 A JP 2009540497A JP 2009540497 A JP2009540497 A JP 2009540497A JP 2010512342 A5 JP2010512342 A5 JP 2010512342A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- halogen
- optionally substituted
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 93
- 125000000217 alkyl group Chemical group 0.000 claims description 74
- 229910052736 halogen Inorganic materials 0.000 claims description 52
- 150000002367 halogens Chemical class 0.000 claims description 52
- -1 chloro, methyl Chemical group 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 3
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 3
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 3
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 230000037365 barrier function of the epidermis Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002615 epidermis Anatomy 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 208000006132 lipodystrophy Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 description 23
- 125000003342 alkenyl group Chemical group 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 102000006255 nuclear receptors Human genes 0.000 description 4
- 108020004017 nuclear receptors Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 125000005157 alkyl carboxy group Chemical group 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000005880 oxathiolanyl group Chemical group 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000005968 oxazolinyl group Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000002769 thiazolinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 125000004445 cyclohaloalkyl Chemical group 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86919806P | 2006-12-08 | 2006-12-08 | |
| US60/869,198 | 2006-12-08 | ||
| PCT/US2007/086787 WO2008073825A1 (en) | 2006-12-08 | 2007-12-07 | Lxr and fxr modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010512342A JP2010512342A (ja) | 2010-04-22 |
| JP2010512342A5 true JP2010512342A5 (https=) | 2012-01-26 |
| JP5399262B2 JP5399262B2 (ja) | 2014-01-29 |
Family
ID=39315799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540497A Expired - Fee Related JP5399262B2 (ja) | 2006-12-08 | 2007-12-07 | Ｌｘｒおよびｆｘｒのモジュレーター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7998995B2 (https=) |
| EP (1) | EP2121621B1 (https=) |
| JP (1) | JP5399262B2 (https=) |
| KR (1) | KR20090094125A (https=) |
| CN (1) | CN101679297B (https=) |
| AU (1) | AU2007333194A1 (https=) |
| NO (1) | NO20092587L (https=) |
| WO (1) | WO2008073825A1 (https=) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1558582E (pt) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| US8703805B2 (en) | 2005-06-27 | 2014-04-22 | Exelixis Patent Company Llc | Modulators of LXR |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| TWI415845B (zh) * | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| TWI443090B (zh) | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物 |
| RS54303B1 (sr) | 2007-07-19 | 2016-02-29 | Lundbeck, H., A/S | 5-člani heterociklični amidi i srodna jedinjenja |
| WO2009023253A2 (en) | 2007-08-15 | 2009-02-19 | Arena Pharmaceuticals Inc. | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
| US7906553B2 (en) * | 2008-08-27 | 2011-03-15 | Calcimedica, Inc. | Substituted thiophene modulators of intracellular calcium |
| NZ592603A (en) * | 2008-10-21 | 2013-02-22 | Metabolex Inc | Aryl gpr120 receptor agonists and uses thereof |
| CN104739829B (zh) | 2008-10-28 | 2018-11-06 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| US8853202B2 (en) | 2008-11-04 | 2014-10-07 | Chemocentryx, Inc. | Modulators of CXCR7 |
| MX2011004490A (es) * | 2008-11-04 | 2011-07-20 | Chemocentryx Inc | Moduladores de cxcr7. |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| WO2010117090A1 (en) * | 2009-04-10 | 2010-10-14 | Banyu Pharmaceutical Co.,Ltd. | Novel isoquinolinyloxymethyl heteroaryl derivatives |
| KR101676704B1 (ko) | 2009-05-28 | 2016-11-16 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | Ｌｘｒ 조절자 |
| GB0910003D0 (en) * | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| DE102009043260A1 (de) * | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| WO2011047156A1 (en) | 2009-10-15 | 2011-04-21 | Hercules Technology Management Co V, Inc. | Sepiapterin reductase inhibitors for the treatment of pain |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8252826B2 (en) * | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US20130274212A1 (en) | 2010-09-07 | 2013-10-17 | Snu R&Db Foundation | Sesterterpene Compounds and Use Thereof |
| WO2012074067A1 (ja) | 2010-12-01 | 2012-06-07 | 日産化学工業株式会社 | 多発性骨髄腫の治療効果を有するピラゾール化合物 |
| TW201242953A (en) * | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| EP2723718A1 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| US8710043B2 (en) | 2011-06-24 | 2014-04-29 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US9289365B2 (en) * | 2011-10-24 | 2016-03-22 | Avon Products, Inc. | Compositions and methods for stimulating collagen synthesis in the skin |
| CN103087041B (zh) * | 2011-11-02 | 2014-06-18 | 中国中化股份有限公司 | 含二芳醚的吡唑酰胺类化合物作为农用杀菌剂的用途 |
| AR088702A1 (es) * | 2011-11-09 | 2014-06-25 | Gruenenthal Gmbh | Derivados de carboxamida y urea, basados en pirazolilo sustituido, que presentan una porcion fenilo sustituida con un grupo que contiene o como ligando de receptor vainilloide |
| AU2012334066A1 (en) * | 2011-11-09 | 2014-05-22 | Grunenthal Gmbh | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an N-containing group as vanilloid receptor ligands |
| DK2820013T3 (en) | 2012-03-02 | 2018-10-29 | Ralexar Therapeutics Inc | Liver X Receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions |
| US9018233B2 (en) | 2012-05-07 | 2015-04-28 | Kyung Nong Corporation | Diaminoaryl derivatives substituted by carbamate and pesticidal composition containing same |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| EP3626309B1 (en) | 2012-08-13 | 2023-03-08 | The Rockefeller University | Lxrbeta agonist for the treatment of cancer |
| JP6272897B2 (ja) | 2012-11-29 | 2018-01-31 | ケモセントリックス，インコーポレイティド | Ｃｘｃｒ７アンタゴニスト |
| EP2928471B1 (en) * | 2012-12-06 | 2020-10-14 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| SG10201707409PA (en) | 2013-03-13 | 2017-10-30 | Forma Therapeutics Inc | Novel compounds and compositions for inhibition of fasn |
| JP6442475B2 (ja) * | 2013-03-15 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| JP6456909B2 (ja) * | 2013-03-15 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| GB2513403A (en) * | 2013-04-26 | 2014-10-29 | Agency Science Tech & Res | WNT pathway modulators |
| JP2016532713A (ja) * | 2013-09-04 | 2016-10-20 | アレクサー セラピューティクス， インク． | 肝臓ｘ受容体（ｌｘｒ）調節因子 |
| PT3041835T (pt) | 2013-09-04 | 2020-07-13 | Ellora Therapeutics Inc | Moduladores de recetor de fígado x (lxr) |
| DK3043865T3 (da) | 2013-09-11 | 2021-02-01 | Univ Claude Bernard Lyon | Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion |
| DK3066085T3 (da) | 2013-11-08 | 2020-06-02 | Incyte Holdings Corp | Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor |
| SG11201605408RA (en) | 2014-01-10 | 2016-07-28 | Aurigene Discovery Tech Ltd | Indazole compounds as irak4 inhibitors |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| FI3805233T3 (fi) | 2014-01-13 | 2024-04-17 | Aurigene Oncology Ltd | N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon |
| CN106257976B (zh) | 2014-03-07 | 2021-02-02 | 拜奥克里斯特制药公司 | 人类血浆激肽释放酶抑制剂 |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| CN104045635A (zh) * | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
| EP3230277B1 (en) * | 2014-12-11 | 2019-09-18 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| TW201628625A (zh) | 2015-02-06 | 2016-08-16 | 英特賽普醫藥品公司 | 組合療法醫藥組成物 |
| TWI698430B (zh) * | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| AU2016233579A1 (en) * | 2015-03-13 | 2017-10-12 | Salk Institute For Biological Studies | Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors |
| AU2016238523A1 (en) | 2015-03-26 | 2017-11-09 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| US10894054B2 (en) | 2015-04-07 | 2021-01-19 | Intercept Pharmaceuticals, Inc. | FXR agonist compositions for combination therapy |
| WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| MX2018014034A (es) * | 2016-05-25 | 2019-08-29 | Akarna Therapeutics Ltd | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |
| MX385718B (es) | 2016-06-13 | 2025-03-18 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4). |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds |
| TW201808283A (zh) * | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| CN108059607B (zh) * | 2016-11-09 | 2020-11-17 | 中国科学院上海药物研究所 | 亚砜基乙酸或砜基乙酸类衍生物、其药物组合物、制备方法和用途 |
| PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
| WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| DK3600270T3 (da) | 2017-03-31 | 2023-07-10 | Aurigene Oncology Ltd | Forbindelser og sammensætninger til behandling af hæmatologiske lidelser |
| WO2018213082A1 (en) | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| CA3079628A1 (en) | 2017-10-31 | 2019-05-09 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
| KR102731924B1 (ko) * | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| MA53455B1 (fr) | 2018-11-20 | 2022-11-30 | Regeneron Pharma | Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| MX2021006915A (es) | 2018-12-12 | 2021-08-24 | Chemocentryx Inc | Inhibidores de cxcr7 para el tratamiento de cancer. |
| EP3911647B1 (en) | 2019-01-15 | 2023-12-13 | Gilead Sciences, Inc. | Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same |
| CA3233305A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| CN114144185A (zh) | 2019-05-30 | 2022-03-04 | 英特塞普特医药品公司 | 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物 |
| KR20220035365A (ko) | 2019-07-18 | 2022-03-22 | 엔요 파마 | 인터페론의 부작용을 감소시키는 방법 |
| CN110713460A (zh) * | 2019-11-08 | 2020-01-21 | 南通大学 | 一种含吡唑苯基单元的吡唑酰胺衍生物的制备方法及其应用 |
| CN114728915B (zh) | 2019-11-26 | 2024-08-30 | 拜耳公司 | [(1,5-二苯基-1h-1,2,4-三唑-3-基)氧基]乙酸衍生物及其盐、包含其的作物保护组合物、其制备方法及其作为安全剂的用途 |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
| WO2021122728A1 (de) | 2019-12-19 | 2021-06-24 | Bayer Aktiengesellschaft | 1,5-diphenylpyrazolyl-3-oxyalkylsäuren und 1-phenyl-5-thienylpyrazolyl-3-oxyalkylsäuren und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists for treating an infection by hepatitis d virus |
| BR112022021901A2 (pt) | 2020-04-29 | 2023-01-17 | Bayer Ag | Ácidos de 1-pirazinilpirazolil-3-oxialquila e seus derivados e seu uso para controle de crescimento indesejado de planta |
| WO2022096450A1 (de) | 2020-11-05 | 2022-05-12 | Bayer Aktiengesellschaft | Verwendung von [(1,5-diphenyl-1h-pyrazol-3-yl)oxy]essigsäure-derivaten und deren salze sowie diese enthaltende mittel, zur reduktion phytotoxischer wirkungen von agrochemikalien, insbesondere von herbiziden, in nutz- oder kulturpflanzen. |
| JP2023548351A (ja) | 2020-11-05 | 2023-11-16 | バイエル・アクチエンゲゼルシヤフト | 有用植物および作物植物の保護のための毒性緩和剤としての［（１－フェニル－５－ヘテロアリール－１ｈ－ピラゾール－３－イル）オキシ］酢酸誘導体 |
| EP4240731A1 (de) | 2020-11-05 | 2023-09-13 | Bayer Aktiengesellschaft | [(1,5-diheteroaryl-1h-1,2,4-triazol-3-yl)oxy]essigsäure-derivate als safener zum schutz von nutz- und kulturpflanzen |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| KR20240004476A (ko) | 2021-04-08 | 2024-01-11 | 쿠리스 인코퍼레이션 | 암 치료를 위한 병용 요법 |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2141916T3 (es) | 1993-11-30 | 2000-04-01 | Searle & Co | Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion. |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US6492411B1 (en) | 1993-11-30 | 2002-12-10 | G. D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| ES2179254T3 (es) | 1996-11-04 | 2003-01-16 | Bayer Cropscience Sa | 1-poliarilpirazoles plaguicidas. |
| WO1998032444A1 (en) | 1997-01-24 | 1998-07-30 | The Regents Of The University Of California | USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION |
| US20020035156A1 (en) | 1997-04-18 | 2002-03-21 | Barbara Roniker | Combination therapy in the prevention of cardiovascular disorders |
| US6294558B1 (en) | 1999-05-31 | 2001-09-25 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
| JP4221129B2 (ja) | 1999-02-15 | 2009-02-12 | 富士フイルム株式会社 | 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子 |
| US6071955A (en) | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
| NZ515086A (en) | 1999-04-28 | 2003-10-31 | Aventis Pharma Gmbh | Di-aryl acid derivatives as PPAR receptor ligands |
| DE60135742D1 (de) | 2000-05-29 | 2008-10-23 | Kyorin Seiyaku Kk | Substituierte phenylpropionsäure-derivate |
| MXPA03011558A (es) | 2001-06-12 | 2004-03-26 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
| US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| AU2003209388A1 (en) | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| CA2485679A1 (en) | 2002-04-08 | 2003-10-23 | The Ohio State University Research Foundation | Compounds and methods for inducing apoptosis in proliferating cells |
| WO2003090732A1 (en) * | 2002-04-23 | 2003-11-06 | Chugai Seiyaku Kabushiki Kaisha | Lxr modulators for the treatment of cardiovascular diseases |
| WO2004011446A1 (en) | 2002-07-26 | 2004-02-05 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
| US7109227B2 (en) | 2002-08-26 | 2006-09-19 | National Health Research Institutes | Imidazolamino compounds |
| EP1398029A1 (en) * | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| JP4631259B2 (ja) | 2002-10-03 | 2011-02-16 | コニカミノルタホールディングス株式会社 | 有機エレクトロルミネッセンス素子及び表示装置 |
| JP4537855B2 (ja) | 2002-10-09 | 2010-09-08 | 久光製薬株式会社 | 抗真菌活性を有する新規ピラゾール化合物 |
| CN1747949A (zh) | 2002-12-20 | 2006-03-15 | 法马西亚公司 | 无环吡唑化合物 |
| AU2003287912A1 (en) | 2002-12-20 | 2004-07-14 | Novo Nordisk A/S | Dicarboxylic acid derivatives as ppar-agonists |
| US7396850B2 (en) | 2003-01-06 | 2008-07-08 | Eli Lilly And Company | Pyrazole derivative as PPAR modulator |
| US7572922B2 (en) * | 2003-01-27 | 2009-08-11 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| JP2006518738A (ja) | 2003-02-12 | 2006-08-17 | トランス テック ファーマ，インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
| US20050113423A1 (en) | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
| AU2004228057A1 (en) | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| DE10315571A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Pyrazolverbindungen |
| DE10315573A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituierte Pyrazole |
| DE10315569A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituierte Pyrazolverbindungen |
| MXPA05012679A (es) | 2003-05-27 | 2006-02-08 | Sod Conseils Rech Applic | Nuevos derivados de imidazoles, su preparacion y su uso como medicamento. |
| WO2005012263A1 (en) | 2003-07-24 | 2005-02-10 | Pharmagene Laboratories Limited | 5-ht2b receptor antagonists |
| MXPA06000933A (es) | 2003-07-25 | 2006-03-30 | Pfizer | Compuestos de aminopirazol y uso como inhibidores de chk1. |
| CA2566846C (en) | 2003-10-03 | 2012-08-28 | The Ohio State University Research Foundation | Pdk-1/akt signaling inhibitors |
| WO2005037199A2 (en) | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| EP1675814A1 (en) | 2003-10-14 | 2006-07-05 | Eli Lilly And Company | Phenoxyether derivatives as ppar modulators |
| WO2005037271A2 (en) | 2003-10-17 | 2005-04-28 | Tanabe Seiyaku Co., Ltd. | Large conductance calcium-activated k channel opener |
| US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
| TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
| US20070082907A1 (en) | 2003-11-25 | 2007-04-12 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| WO2005066137A1 (en) | 2003-12-19 | 2005-07-21 | Neurogen Corporation | 2,5-diaryl-1h-imidazole-4-carboxamides as neurokinin-3 receptor modulators for the treatment of central nervous system and peripheral diseases |
| CA2584317A1 (en) | 2004-10-15 | 2006-04-27 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| TW200619191A (en) * | 2004-10-27 | 2006-06-16 | Sankyo Co | Phenyl compounds with more than 2 substitutes |
| WO2006076202A1 (en) * | 2005-01-10 | 2006-07-20 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptors ligands |
| EP1884513A4 (en) | 2005-05-23 | 2010-04-28 | Japan Tobacco Inc | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME |
| US8703805B2 (en) * | 2005-06-27 | 2014-04-22 | Exelixis Patent Company Llc | Modulators of LXR |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
-
2007
- 2007-12-07 KR KR1020097013701A patent/KR20090094125A/ko not_active Withdrawn
- 2007-12-07 EP EP07865385.4A patent/EP2121621B1/en active Active
- 2007-12-07 JP JP2009540497A patent/JP5399262B2/ja not_active Expired - Fee Related
- 2007-12-07 WO PCT/US2007/086787 patent/WO2008073825A1/en not_active Ceased
- 2007-12-07 CN CN2007800511486A patent/CN101679297B/zh not_active Expired - Fee Related
- 2007-12-07 AU AU2007333194A patent/AU2007333194A1/en not_active Abandoned
- 2007-12-07 US US12/517,800 patent/US7998995B2/en active Active
-
2009
- 2009-07-07 NO NO20092587A patent/NO20092587L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010512342A5 (https=) | ||
| JP2012520866A5 (https=) | ||
| JP2022500392A5 (https=) | ||
| JP2011510080A5 (https=) | ||
| JP2018518537A5 (https=) | ||
| EA028079B1 (ru) | Определенные аминопиримидины, композиции на их основе и способы их использования | |
| JP2009197008A5 (https=) | ||
| CN104739841A (zh) | 合成三萜类化合物及用以治病之方法 | |
| RU2019134558A (ru) | Композиции и способы лечения анемии | |
| CN106413666A (zh) | 牙科用粘固剂 | |
| JP2017504649A5 (https=) | ||
| JP2012523395A5 (https=) | ||
| JP2003515523A5 (https=) | ||
| CN116615217A (zh) | 炎症性疾病和/或疼痛性疾病的预防或治疗药 | |
| JP2017518360A5 (https=) | ||
| US20230365572A1 (en) | Hydroxylbenzyl azabicyclo[2.2.1]heptan-1-ane drivatives and medical uses thereof | |
| EP4217344A1 (en) | Arylazabicyclo[2.1.1]hexylmethanol derivatives and medical uses thereof | |
| JP2024096817A (ja) | インドール化合物を用いた疼痛又は間質性膀胱炎の治療方法 | |
| CN106456646B (zh) | 用于治疗或预防肾结石症的可可碱或其衍生物 | |
| MX2014008484A (es) | Agente terapeutico para la diabetes mellitus. | |
| TW201628623A (zh) | 尿酸性或痛風性疾病的預防或治療 | |
| JP5973455B2 (ja) | 脱髄疾患の治療薬及び予防薬 | |
| TWI411435B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於治療脊髓創傷之用途 | |
| CN117813098A (zh) | 治疗疾病或病症的方法 | |
| PT787491E (pt) | Composicao para a profilaxia e para o tratamento de doencas alergicas de tipo i |